Core Viewpoint - The article highlights the significant contributions of Li Kang, a key figure in the development of the PD-1 drug, Tislelizumab (百泽安), at BeiGene, and reflects on his legacy following his recent passing due to a brain hemorrhage at the age of 69 [2][3]. Group 1: Contributions and Achievements - Li Kang was the principal inventor of Tislelizumab, recognized as the "father of 百泽安," and played a crucial role in establishing the biopharmaceutical department at BeiGene after joining in August 2011 [2]. - Tislelizumab is BeiGene's second-largest product and the highest-grossing domestic PD-1 drug, with total sales reaching 16.5 billion yuan and approvals in 47 global markets [2]. - Li Kang's efforts were instrumental in generating nearly 1 billion USD in net profit for the company through two key business development deals during its early challenging years [3]. Group 2: Personal Background and Legacy - Li Kang had nearly 30 years of experience in biomedical research, particularly in tumor biology, antibody drug development, and tumor immunotherapy, holding a master's degree from Wuhan University and a Ph.D. from Emory University [3]. - His personal journey included significant sacrifices, such as selling his home in San Diego and relocating to Beijing with his wife to pursue his vision of developing better cancer therapies [2]. - Following his death, BeiGene's co-founder Wang Xiaodong shared memories of their time together, emphasizing Li Kang's impact on the company and the lives of cancer patients [2][3].
百济神州“PD-1之父”李康因病去世